Vanda Pharmaceuticals Inc. — Director's Dealing 2022

Jun 2, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vanda Pharmaceuticals Inc. (VNDA)
CIK: 0001347178
Period of Report: 2022-05-31

Reporting Person: DUGAN RICHARD W (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-05-31	Common Stock	M	15000	$4.15	Acquired	74887	Direct
2022-05-31	Common Stock	S	6500	$9.8542	Disposed	68387	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-05-31	Stock Option (Right to Buy)	$4.15	M	15000	Disposed	2022-06-13	Common Stock (15000)	Direct

Footnotes

F1: Represents shares of the Issuer's common stock sold to satisfy the exercise price of the stock options, which were scheduled to expire June 13, 2022 as reflected in this Form 4.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.75 to $9.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

F3: The option vested in 12 equal monthly installments beginning on July 14, 2012.